Research progress of DNA-PK inhibitors in the cancer treatment
10.16438/j.0513-4870.2023-0486
- VernacularTitle:靶向DNA-PK的抗肿瘤药物研发进展
- Author:
Tian CAI
;
Bing-hao KANG
;
Yue CHENG
;
Min HUANG
;
Lin-xiang ZHAO
- Publication Type:Research Article
- Keywords:
DNA damage;
anti-tumor;
DNA-dependent protein kinase;
inhibitor
- From:
Acta Pharmaceutica Sinica
2023;58(8):2218-2225
- CountryChina
- Language:Chinese
-
Abstract:
The most toxic DNA damage is DNA double strand breaks (DSBs), which are mainly repaired by non-homologous end joining (NHEJ). DNA-dependent protein kinase (DNA-PK) belongs to phosphatidylinositol-3-kinase-related protein kinase family (PIKK) and plays a key role in NHEJ. DNA-PK is overexpressed in a variety of cancer cells and is related to the occurrence, development and drug resistance of malignant tumors. In this article, the representative DNA-PK inhibitors with anticancer effects are reviewed, in order to provide a reference to discovery novel DNA-PK inhibitors.
